title: CYP2D6 T188C variant is associated with lung cancer risk in the Chinese population.
abstract: The CYP2D6 gene has been suggested to play an important role in the pathogenesis of lung cancer. However, the results have been inconsistent. In this study, we performed a meta-analysis to clarify the association of CYP2D6 T188C variant with lung cancer. Published literature from PubMed, Embase, Chinese National Knowledge Infrastructure and Wanfang data were retrieved. Pooled odds ratio (OR) with 95 % confidence interval (CI) was calculated using fixed- or random-effects model. A total of nine studies (1,516 lung cancer cases and 1,950 controls) for CYP2D6 T188C variant were included in the meta-analysis. The meta-analysis indicated that compared with CYP2D6 TT genotype, non-TT genotype (CC or CT) was significantly associated with lung cancer in the Chinese (OR = 1.61, 95 % CI = 1.38-1.87, p < 0.001), with no evidence of between-study heterogeneity (I (2) = 0.0 %, p = 0.991). The sensitivity analysis indicated that the association was stable and no publication bias was detected. The present meta-analysis supported the positive association of CYP2D6 T188C variant with lung cancer in the Chinese. Further large-scale studies with the consideration for gene-gene/gene-environment interactions should be conducted to investigate the association.
authors.affiliation: University of South China, Hengyang, China.
authors.forename: Yan
authors.initials: Y
authors.lastname: Huang
authors.forename: Xin
authors.initials: X
authors.lastname: Liu
authors.forename: Xin
authors.initials: X
authors.lastname: Kuang
authors.forename: Duanfang
authors.initials: D
authors.lastname: Liao
mesh_terms: D002681:China; D019389:Cytochrome P-450 CYP2D6 / Q000235:genetics*; D056726:Genetic Association Studies; D020022:Genetic Predisposition to Disease; D006801:Humans; D008175:Lung Neoplasms / Q000235:genetics*; D020641:Polymorphism, Single Nucleotide; D012306:Risk
chemical_list: D019389:Cytochrome P-450 CYP2D6
references.citation: Pharmacogenomics. 2002 Mar;3(2):229-43
references.pmid: 11972444
references.citation: Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2008 Oct;30(5):564-8
references.pmid: 19024387
references.citation: Lancet. 2011 Nov 12;378(9804):1741-55
references.pmid: 21565397
references.citation: BMJ. 1997 Sep 13;315(7109):629-34
references.pmid: 9310563
references.citation: Zhongguo Fei Ai Za Zhi. 2004 Apr 20;7(2):112-7
references.pmid: 21215003
references.citation: Asian Pac J Cancer Prev. 2012;13(7):3165-72
references.pmid: 22994728
references.citation: J Natl Cancer Inst. 1959 Apr;22(4):719-48
references.pmid: 13655060
references.citation: Control Clin Trials. 1986 Sep;7(3):177-88
references.pmid: 3802833
references.citation: Zhongguo Fei Ai Za Zhi. 2005 Apr 20;8(2):89-94
references.pmid: 21189172
references.citation: Biometrics. 1994 Dec;50(4):1088-101
references.pmid: 7786990
references.citation: Zhonghua Liu Xing Bing Xue Za Zhi. 2004 Dec;25(12):1042-5
references.pmid: 15769360
references.citation: Pharmacol Ther. 1993 Feb-Mar;57(2-3):129-60
references.pmid: 8361990
references.citation: Genes Chromosomes Cancer. 2011 Jan;50(1):1-12
references.pmid: 20842733
references.citation: Mutat Res. 1999 Aug 18;444(2):441-9
references.pmid: 10521684
references.citation: Eur J Clin Pharmacol. 1997;51(5):389-93
references.pmid: 9049580
references.citation: Zhonghua Yi Xue Za Zhi. 2007 Nov 20;87(43):3064-8
references.pmid: 18261353